NCT03876587: Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system metastasis; Patients that have used tyrosine kinase inhibitors targeting HER2 (neratinib, lapatinib, pyrotinib, etc.)

Comments are closed.

Up ↑